AVLN (Avalyn Pharma) Stock Based Compensation: $3.27 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVLN Avalyn Pharma Inc AVLN
11 GF Score
Price $28.50
View Full Analysis

What is Avalyn Pharma Stock Based Compensation?

Avalyn Pharma AVLN -1.01% 11 Stock Based Compensation is $3.27 Mil as of Dec. 2025. GuruFocus rates AVLN with a GF Score™ of 11/100.

Avalyn Pharma's Stock Based Compensation for the six months ended in Dec. 2025 was $3.27 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $3.27 Mil.

Avalyn Pharma Stock Based Compensation Related Terms

Avalyn Pharma Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Avalyn Pharma's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalyn Pharma Stock Based Compensation Chart

Avalyn Pharma Annual Data
Trend Dec24 Dec25
Stock Based Compensation
2.47 3.27

Avalyn Pharma Semi-Annual Data
Dec24 Dec25
Stock Based Compensation 2.47 3.27
AVLN
11GF Score
Avalyn Pharma Inc AVLN
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalyn Pharma Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $3.27 Mil.

What does a Stock Based Compensation of $3.27 Mil mean?
Avalyn Pharma (AVLN) has a Stock Based Compensation of $3.27 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Avalyn Pharma and its competitors.
Is Avalyn Pharma's Stock Based Compensation too high?
Avalyn Pharma's current Stock Based Compensation is $3.27 Mil. Overall, Avalyn Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's Stock Based Compensation compare to TRAX and IMTX?
Avalyn Pharma's Stock Based Compensation of $3.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Avalyn Pharma and its competitors. Avalyn Pharma's current Stock Based Compensation is $3.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current Stock Based Compensation of $3.27 Mil. The current Stock Based Compensation is $3.27 Mil. Avalyn Pharma's overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current Stock Based Compensation is $3.27 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avalyn Pharma Business Description

Address 105 W First Street, Boston, MA, USA, 02127
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
11GF Score

Get the complete analysis for AVLN

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.50
Price